M. J. Sonneveld Et Al. , "Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)," 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , vol.56, Massachusetts, United States Of America, 2012
Sonneveld, M. J. Et Al. 2012. Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study). 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , (Massachusetts, United States Of America).
Sonneveld, M. J., Xie, Q., Zhang, N., Zhang, Q., Tabak, F., Streinu-cercel, A., ... Wang, J.(2012). Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study) . 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America
Sonneveld, Milan Et Al. "Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)," 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 2012
Sonneveld, Milan J. Et Al. "Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)." 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2012
Sonneveld, M. J. Et Al. (2012) . "Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)." 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={Milan J. Sonneveld Et Al. }, title={Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)}, congress name={63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)}, city={Massachusetts}, country={United States Of America}, year={2012}}